市場調査レポート

商品コード

1371897

バイオディフェンス市場の2030年までの予測：製品別、検出装置別、用途別、エンドユーザー別、地域別の世界分析

Biodefense Market Forecasts to 2030 - Global Analysis By Product (Anthrax, Botulism, Cholera, Influenza and Other Products), Detection Device, Application, End User and By Geography

出版日: 2023年10月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,554円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,990円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 995,426円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,175,700円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ストラティスティックスMRCによると、世界のバイオディフェンス市場は2023年に162億米ドルを占め、予測期間中のCAGRは7.0％で成長し、2030年には261億米ドルに達する見込みです。

生物兵器、バイオテロリズム、自然発生感染症などの生物学的脅威から身を守り、対処するための予防措置と対応システムは、「バイオディフェンス」と呼ばれます。バイオディフェンス」とは、人間の健康、国家の安全保障、国際的な平和と安全を守るための幅広い取り組み、規制、手続きを指します。バイオディフェンスの目的は、細菌、ウイルス、毒物、その他の微生物など、人や動物、植物に危害を加える生物学的病原体がもたらす危険から身を守ることです。

連邦研究開発（R&D）資金によると、2017会計年度に連邦政府8機関が獲得した資金総額の96.3％を国防総省（39.3％）と保健福祉省（27.3％）が獲得しました。

研究開発への比重の高まり

有能なバイオディフェンスシステムの構築と人類の健康保全は、どちらも新技術の開発に大きく依存しています。臨床試験の継続的な増加と研究開発費の増加は、バイオディフェンス産業の成長を促進する2つの大きな要因です。例えば、2020年4月にEmergent Bio Solutionsと米国政府との間でパートナーシップ協定が締結されました。この協定の目的は、COVID-19患者のための血漿由来治療薬の開発を容易にすることでした。さらに、米国保健社会福祉省（HHS）の準備・対応担当次官補室（ASPR）の一部門であるバイオメディカル先端研究開発局（BARDA）は、Emergent社が発表した2つの超免疫開発プログラムのうちの1つであるCOVID-HIGプログラムを支援するため、Emergent社にUSDを授与しました。したがって、構造化された規制と新分子の開発に関するすべてのイニシアチブが市場を牽引しています。

倫理的配慮

バイオテロや新種の感染症などの生物学的脅威から公衆衛生、国家安全保障、世界的安定を守ろうとする試みからなるバイオディフェンスというテーマでは、倫理的問題が最も重要です。バイオディフェンスにおける政策、実践、調査は、即応性の要求と道徳的に正しい行動との間のバランスを取ろうとする、こうした倫理的配慮に導かれています。数多くの生物防御研究プロジェクトは二重使用の可能性を持っています。つまり、有害な目的にも合法的な科学的目的にも使用される可能性があり、市場の妨げとなっています。

政府の有益な取り組み

先進国の政府は、このような攻撃に耐えられるよう、さまざまな行動をとり、予防策を講じています。国民を守るため、政府はワクチンや生物脅威を特定するツールの在庫を定期的に確保しています。これは、連邦政府による多額の資金援助、技術の進歩、国民の意識の高まりによるものです。生物学的伝染病が発生した場合、緊急対応能力を向上させ、生物医学の技術革新を刺激・促進し、生物脅威の発生源を突き止め、無力化することを目的とした戦略です。地域のバイオディフェンス市場は、こうした政府の動きによって刺激を受けています。

高コスト

研究、開発、医療対抗措置の備蓄、即応措置を含む高度なバイオディフェンスシステムは、その構築と維持にコストがかかります。生物防御の資金調達プログラムは、ヘルスケアや国家安全保障上の懸念との競合に直面することが多いです。さらに、さまざまな生物学的脅威や病原体に対処することも、生物防衛の一部です。このような多くの化学物質に対する防御を構築するには、高度な科学的・技術的知識が要求されます。

COVID-19の影響

COVID-19はヘルスケア分野全体に大きな影響を与えます。2022年5月の災害医療公衆衛生緊急事態の記事によると、COVID-19パンデミックの出現は、人々の生活だけでなく、経済や社会の安定にも大きな影響を及ぼしています。この研究では、パンデミック発生時に検査やサーベイランスが不十分であったため、ヘルスケアシステム全体に問題が広がったことが示されました。バイオの脅威は、米国とその国際的利益にとって、今後も課題的で重大なリスクであり続けると予想されます。COVID-19は結果的にバイオディフェンス分野に影響を与えました。

炭疽菌セグメントは予測期間中最大となる見込み

炭疽菌セグメントは、グラム陽性で棒状の炭疽菌が致命的な感染症である炭疽の発生源であるため、有利な成長を遂げると推定されます。家畜も野生動物も、土壌中で自然に発生するこの菌の影響を世界中で頻繁に受けています。もし人々が病気の動物や汚染された動物性食品に接触すれば、炭疽病にかかる可能性があります。炭疽菌の症状を理解し、発生時やバイオテロ事件発生時に正しく対応できるよう、人々や医療従事者の意識を高め、確実にすることは、公衆教育プログラムの重要な目標であり、バイオディフェンス市場を強化するものです。

アッセイ分野は予測期間中に最も高いCAGRが見込まれる

環境、国家安全保障、公衆衛生を危険にさらす可能性のある生物製剤や病原体を発見し、説明し、特徴付けるために使用されるため、アッセイ分野は予測期間中に最も高いCAGRの成長が見込まれています。これらの検査は、バイオテロや新たに発生した感染症などの生物学的脅威の監視、準備、対応に不可欠です。質量分析、フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、酵素結合免疫吸着測定法（ELISA）、免疫蛍光法などは、ハザードを特定するために使用されるいくつかのアッセイです。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されます。これは、北米におけるバイオディフェンス市場の主な成長促進要因である、政府のイニシアチブの高まりと実地調査における研究開発のためです。例えば、National Association of County and City Health Officialsの2021年報告書によると、National Health Security Strategy（NHSS）とNational Biodefense Strategy（NBS）は、感染症や生物学的脅威に対抗するための予防、準備、対応、回復、緩和の取り組みを通じて、米国の健康安全保障事業を推進することに重点を置いています。さらに、NBSと国家安全保障大統領覚書14は、生物学的脅威から米国民を守るため、米国政府全体で実施されるあらゆる生物防衛行動を調整する指導体制と戦略を確立し、この地域の市場成長を牽引しています。

CAGRが最も高い地域：

アジア太平洋地域は、研究開発費の増加、生物防御の重要性の高まり、緊急事態を引き起こす危険な生物学的物質がもたらす脅威により、予測期間中のCAGRが最も高くなると予測されています。ワクチン開発のための確立された施設が存在するため、オーストラリアと日本はアジア太平洋地域で最も発達したバイオディフェンス産業の2つを持っています。将来の生物学的危険に備えるため、中国やインドのような国々は研究開発能力を積極的に強化しています。これらは、この地域のバイオディフェンス市場を推進している要因です。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Siga Technologies Inc.
Emergent BioSolutions Inc.
Ichor Medical Systems
National Resilience, Inc.
Bavarian Nordic
Dynavax Technologies
Nighthawk Biosciences, Inc.
XOMA Corporation
Dynport Vaccine Company
Cleveland Biolabs
Ology Bioservices
Alnylam Pharmaceuticals Inc.
XOMA corporation
Altimmune Inc.
Biosearch Technologies
Bruker Detection

図表

List of Tables

Table 1 Global Biodefense Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 4 Global Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 5 Global Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 6 Global Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 7 Global Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 8 Global Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 9 Global Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 10 Global Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 11 Global Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 12 Global Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 13 Global Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 14 Global Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 15 Global Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 16 Global Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 17 Global Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 18 Global Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 19 Global Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 20 Global Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 21 Global Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 22 Global Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 23 Global Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 24 Global Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
Table 25 North America Biodefense Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 27 North America Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 28 North America Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 29 North America Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 30 North America Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 31 North America Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 32 North America Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 33 North America Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 34 North America Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 35 North America Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 36 North America Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 37 North America Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 38 North America Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 39 North America Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 40 North America Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 41 North America Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 42 North America Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 43 North America Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 44 North America Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 45 North America Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 46 North America Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 47 North America Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 48 North America Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
Table 49 Europe Biodefense Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 51 Europe Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 52 Europe Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 53 Europe Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 54 Europe Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 55 Europe Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 56 Europe Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 57 Europe Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 58 Europe Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 59 Europe Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 60 Europe Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 61 Europe Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 62 Europe Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 63 Europe Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 64 Europe Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 65 Europe Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 66 Europe Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 67 Europe Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 68 Europe Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 69 Europe Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 70 Europe Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 71 Europe Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 72 Europe Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 Asia Pacific Biodefense Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 75 Asia Pacific Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 76 Asia Pacific Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 77 Asia Pacific Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 78 Asia Pacific Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 79 Asia Pacific Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 80 Asia Pacific Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 81 Asia Pacific Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 82 Asia Pacific Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 83 Asia Pacific Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 84 Asia Pacific Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 85 Asia Pacific Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 86 Asia Pacific Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 87 Asia Pacific Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 88 Asia Pacific Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 89 Asia Pacific Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 90 Asia Pacific Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 91 Asia Pacific Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 92 Asia Pacific Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 93 Asia Pacific Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 94 Asia Pacific Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 95 Asia Pacific Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 96 Asia Pacific Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
Table 97 South America Biodefense Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 99 South America Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 100 South America Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 101 South America Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 102 South America Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 103 South America Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 104 South America Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 105 South America Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 106 South America Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 107 South America Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 108 South America Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 109 South America Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 110 South America Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 111 South America Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 112 South America Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 113 South America Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 114 South America Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 115 South America Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 116 South America Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 117 South America Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 118 South America Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 119 South America Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 120 South America Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
Table 121 Middle East & Africa Biodefense Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa Biodefense Market Outlook, By Product (2021-2030) ($MN)
Table 123 Middle East & Africa Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
Table 124 Middle East & Africa Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
Table 125 Middle East & Africa Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
Table 126 Middle East & Africa Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
Table 127 Middle East & Africa Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
Table 128 Middle East & Africa Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
Table 129 Middle East & Africa Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
Table 130 Middle East & Africa Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
Table 131 Middle East & Africa Biodefense Market Outlook, By Assays (2021-2030) ($MN)
Table 132 Middle East & Africa Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
Table 133 Middle East & Africa Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
Table 134 Middle East & Africa Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
Table 135 Middle East & Africa Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
Table 136 Middle East & Africa Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
Table 137 Middle East & Africa Biodefense Market Outlook, By Application (2021-2030) ($MN)
Table 138 Middle East & Africa Biodefense Market Outlook, By Military (2021-2030) ($MN)
Table 139 Middle East & Africa Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
Table 140 Middle East & Africa Biodefense Market Outlook, By End User (2021-2030) ($MN)
Table 141 Middle East & Africa Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 142 Middle East & Africa Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
Table 143 Middle East & Africa Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
Table 144 Middle East & Africa Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC23954

According to Stratistics MRC, the Global Biodefense Market is accounted for $16.2 billion in 2023 and is expected to reach $26.1 billion by 2030 growing at a CAGR of 7.0% during the forecast period. A system of precautions and responses put in place to guard against and address biological threats, notably those posed by biological weapons, bioterrorism, and naturally occurring infectious diseases, is referred to as "biodefense," which is short for "biological defense." The term "biodefense" refers to a broad range of initiatives, regulations, and procedures designed to protect human health, national security, and international peace and security. The goal of biodefense is to defend against dangers posed by biological agents, such as bacteria, viruses, poisons, and other microorganisms that can harm people, animals, or plants.

According to Federal Research and Development (R&D) Funding, the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) got 96.3% of the total funding obtained by eight federal agencies during the 2017 fiscal year.

Market Dynamics:

Driver:

Increasing emphasis on research and development

The building of a competent biodefense system as well as the preservation of human health both largely rely on new technology development. The on-going increase in clinical trials and increased R&D spending are two major factors fuelling the growth of the biodefense industry. For instance, a partnership agreement between Emergent Bio Solutions and the US government was signed in April 2020. The goal of this agreement was to make it easier to develop a plasma-derived treatment for COVID-19 patients. Additionally, Biomedical Advanced Research and Development Authority (BARDA), a section of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), awarded Emergent USD to support its COVID-HIG program, one of two hyper immune development programs that Emergent announced. Hence all the initiatives on developing structured regulations and new molecules are driving the market.

Restraint:

Ethical considerations

In the subject of biodefense, which comprises attempts to safeguard public health, national security, and global stability against biological threats, such as bioterrorism and new infectious illnesses, ethical issues are of utmost importance. Policies, practices, and research in biodefense are guided by these ethical considerations, which seek to strike a balance between the requirement for readiness and morally righteous behaviour. Numerous biodefense research projects have the potential for dual use, which means they could be employed for both harmful and legitimately scientific objectives hinder the market.

Opportunity:

Beneficial government initiatives

Governments in industrialized countries take a number of actions and implement precautionary measures to be prepared to withstand these attacks. To safeguard the public, the government regularly maintains stocks of vaccines and tools for identifying biothreats. This is attributed to significant federal funding, technological advancements, and growing public awareness. The fact that major businesses are present here is also encouraging for the sector in the event of biological epidemics, the strategy aims to improve emergency response capabilities, stimulate and promote biomedical innovation, and locate and neutralize biothreats at their source. The regional biodefense market is being stimulated by these governmental actions.

Threat:

High cost

A sophisticated biodefense system, which includes research, development, stockpiling of medical countermeasures, and readiness measures, is costly to build and sustain. Programs for biodefense funding frequently face competition from healthcare and national security concerns. Moreover, dealing with a variety of biological threats and agents is part of biodefense. Creating defences against these many chemicals demands a high level of scientific and technical knowledge.

COVID-19 Impact

The COVID-19 has a big effect on the entire healthcare sector. According to an article from disaster medicine public health emergency from May 2022, the appearance of the COVID-19 pandemic has had a significant influence on people's lives as well as the stability of the economy and society. The study showed that there was a lack of testing and surveillance during the pandemic outbreak, which resulted in a widespread problem throughout the entire healthcare system. Bio threats are expected to remain challenging and significant risks to the United States and its international interests. COVID-19 consequently had an impact on the biodefense sector.

The anthrax segment is expected to be the largest during the forecast period

The anthrax segment is estimated to have a lucrative growth, because bacillus anthracis gram-positive, rod-shaped bacteria, is the source of the deadly infectious illness anthrax. Animals both domestic and wild are frequently impacted worldwide by this natural occurrence in soil. If people come into contact with diseased animals or contaminated animal products, they could become ill with anthrax. Raising awareness and ensuring that people and healthcare professionals understand the symptoms of anthrax and react correctly in the case of an outbreak or a bioterrorism incident are essential goals of public education programs are enhancing the biodefense market.

The assays segment is expected to have the highest CAGR during the forecast period

The assays segment is anticipated to witness the highest CAGR growth during the forecast period, as these are used to find, describe, and characterize biological agents and pathogens that could endanger the environment, national security, or public health, biodefense assays are specialized testing and analytical techniques. These tests are essential for monitoring, getting ready for, and responding to biological threats like bioterrorism and newly developing infectious illnesses. Mass spectrometry, flow cytometry, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and immunofluorescence these are a few assays that are used to identify hazards.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to increased government initiatives and research and development in field studies are the main growth drivers of the biodefense market in North America. For instance, the National Health Security Strategy (NHSS) and National Biodefense Strategy (NBS) focused on advancing the United States health security enterprise through prevention, preparedness, response, recovery, and mitigation efforts to combat infectious disease and biological threats, according to the 2021 report from the National Association of County and City Health Officials. Moreover, The NBS and National Security Presidential Memorandum 14 also established a leadership structure and strategy to coordinate the full range of biodefense actions carried out across the U.S. Government in order to protect the American people from biological threats is driving the regions market growth.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to rising R&D spending, and the growing importance of biodefense and the threat posed by dangerous biological materials that cause emergencies. Due to the presence of established facilities for the development of vaccines, Australia and Japan have two of the most developed biodefense industries in the Asia Pacific region. To prepare for future biological dangers, nations like China and India are aggressively enhancing their R&D capacities. These are the contributing factors which are propelling the biodefense market in this region.

Key players in the market:

Some of the key players profiled in the Biodefense Market include: Siga Technologies Inc., Emergent BioSolutions Inc., Ichor Medical Systems, National Resilience, Inc., Bavarian Nordic, Dynavax Technologies, Nighthawk Biosciences, Inc., XOMA Corporation Dynport Vaccine Company, Cleveland Biolabs, Ology Bioservices, Alnylam Pharmaceuticals Inc., XOMA Corporation, Altimmune Inc., Biosearch Technologies and Bruker Detection

Key Developments:

In August 2023, Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position. Additionally, Emergent will reduce operations at its facility in Canton, Massachusetts, in response to changes in the volume of U.S. government procurements of medical countermeasures.

In July 2023, SIGA Technologies, Inc. a announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

In July 2023, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease.

Products Covered:

Anthrax
Botulism
Cholera
Influenza
Nuclear
Smallpox
Other Products

Detection Devices Covered:

Assays
Identifiers
Samplers
Detectors
Triggering Devices
Other Detection Devices

Applications Covered:

Military
Civilian

End Users Covered:

Hospitals & Clinics
Ambulatory Care Centers
Government Institutions
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Biodefense Market, By Product

5.1 Introduction
5.2 Anthrax
5.3 Botulism
5.4 Cholera
5.5 Influenza
5.6 Nuclear
5.7 Smallpox
5.8 Other Products

6 Global Biodefense Market, By Detection Device

6.1 Introduction
6.2 Assays
6.3 Identifiers
6.4 Samplers
6.5 Detectors
6.6 Triggering Devices
6.7 Other Detection Devices

7 Global Biodefense Market, By Application

7.1 Introduction
7.2 Military
7.3 Civilian

8 Global Biodefense Market, By End User

8.1 Introduction
8.2 Hospitals & Clinics
8.3 Ambulatory Care Centers
8.4 Government Institutions
8.5 Other End Users

9 Global Biodefense Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Siga Technologies Inc.
11.2 Emergent BioSolutions Inc.
11.3 Ichor Medical Systems
11.4 National Resilience, Inc.
11.5 Bavarian Nordic
11.6 Dynavax Technologies
11.7 Nighthawk Biosciences, Inc.
11.8 XOMA Corporation
11.9 Dynport Vaccine Company
11.10 Cleveland Biolabs
11.11 Ology Bioservices
11.12 Alnylam Pharmaceuticals Inc.
11.13 XOMA corporation
11.14 Altimmune Inc.
11.15 Biosearch Technologies
11.16 Bruker Detection